EFFECTS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX ON MORTALITY IN ACUTE MYOCARDIAL-INFARCTION

被引：13

作者：

HELD, PH ^{[1
]}

TEO, KK ^{[1
]}

YUSUF, S ^{[1
]}

机构：

[1] NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, CLIN TRIALS BRANCH, FED BLDG, BETHESDA, MD 20892 USA

来源：

CIRCULATION | 1990年 / 82卷 / 05期

关键词：

Clinical trials; Meta-analysis; Thrombolysis;

D O I：

10.1161/01.CIR.82.5.1668

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29% by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. Although the beneficial effects of both agents are consistent and are strengthened when all the trials are considered together, the available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase.

引用

页码：1668 / 1674

页数：7

共 30 条

[1] DEVELOPMENT AND EVALUATION OF ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX (APSAC) AS A 2ND GENERATION THROMBOLYTIC AGENT [J].

ANDERSON, JL .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (05) :B22-B27

[2]

[Anonymous], 1988, LANCET, V2, P349

[3]

[Anonymous], 1986, LANCET, V1, P397

[4] TISSUE PLASMINOGEN-ACTIVATOR - TORONTO (TPAT) PLACEBO-CONTROLLED RANDOMIZED TRIAL IN ACUTE MYOCARDIAL-INFARCTION [J].

ARMSTRONG, PW ;

BAIGRIE, RS ;

DALY, PA ;

HAQ, A ;

GENT, M ;

ROBERTS, RS ;

FREEMAN, MR ;

BURNS, R ;

LIU, P ;

MORGAN, CD .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 13 (07) :1469-1476

[5] LIMITATION OF MYOCARDIAL INFARCT SIZE AND PRESERVATION OF LEFT-VENTRICULAR FUNCTION BY EARLY ADMINISTRATION OF APSAC IN MYOCARDIAL-INFARCTION [J].

BASSAND, JP ;

MACHECOURT, J ;

CASSAGNES, J ;

LUSSON, JR ;

BOREL, E ;

SCHIELE, F .

AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (02) :A18-A23

[6]

BEEN M, 1985, BRIT HEART J, V53, P253

[7] SAFETY AND TOLERANCE DATA FROM THE BELGIAN MULTICENTER STUDY OF ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX VERSUS HEPARIN IN ACUTE MYOCARDIAL-INFARCTION [J].

BOSSAERT, LL .

DRUGS, 1987, 33 :287-292

[8]

CHAMBERLAIN DA, 1988, LANCET, V1, P545

[9]

CHAMBERLAIN DA, 1990, LANCET, V335, P427

[10] CORONARY THROMBOLYSIS WITH RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR - A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL [J].

COLLEN, D ;

TOPOL, EJ ;

TIEFENBRUNN, AJ ;

GOLD, HK ;

WEISFELDT, ML ;

SOBEL, BE ;

LEINBACH, RC ;

BRINKER, JA ;

LUDBROOK, PA ;

YASUDA, I ;

BULKLEY, BH ;

ROBISON, AK ;

HUTTER, AM ;

BELL, WR ;

SPADARO, JJ ;

KHAW, BA ;

GROSSBARD, EB .

CIRCULATION, 1984, 70 (06) :1012-1017

← 1 2 3 →